Short Interest in Enzolytics, Inc. (OTCMKTS:ENZC) Expands By 324,082.8%

Enzolytics, Inc. (OTCMKTS:ENZC) saw a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 677,542 shares, a growth of 324,082.8% from the January 15th total of 209 shares. Based on an average daily trading volume, of 7,284,850 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 7,284,850 shares, the days-to-cover ratio is presently 0.1 days.

Enzolytics Stock Performance

OTCMKTS:ENZC remained flat at $0.00 during trading hours on Tuesday. The company’s stock had a trading volume of 4,233,549 shares, compared to its average volume of 5,148,373. Enzolytics has a one year low of $0.00 and a one year high of $0.00.

Enzolytics Company Profile

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.